Trial Tokenization And Linking To Real World Data: Extending The Effectiveness And Safety Analysis Of A New Focal Seizure Treatment
Source: Datavant
Recently, a biopharmaceutical company completed at 36 week Phase IV study of 175 patients across 40 trial sites to evaluate the effectiveness and safety of a recently approved anti-seizure medication as adjunctive therapy in focal seizure. Patient retention was the primary efficacy endpoint and seizure frequency was a secondary efficacy endpoint. The study also looked at tolerability. The initial study results showed that a substantial number of patients remained on therapy and experienced reduced seizure frequency. Read the available case study to find out more.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
Datavant
This website uses cookies to ensure you get the best experience on our website. Learn more